74
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: not found

      Use of whole exome sequencing to determine the genetic basis of multiple mitochondrial respiratory chain complex deficiency

      research-article
      , PhD FRCPath 1 , , PhD 2 , , PhD 2 , , PhD 1 , , PhD 2 , , PhD 1 , , BSc 2 , , BSc 1 , , PhD 2 , , PhD 2 , , PhD 1 , , MD 3 , , MD 4 , , MD 5 , , MD 5 , , MD 6 , , MD 7 , , MD 7 , , MD 7 , , MD 7 , , PhD FRCPCH 8 , , FRCPCH 9 , , MD FRCPI 1 , , MD FRCPCH 10 , , PhD FRCP FMedSci 1 , , PhD 2 , , PhD FRCPCH 1 , 10 ,   , MD PhD 2 , , PhD FRCP FMedSci 2
      JAMA

      Read this article at

      ScienceOpenPublisherPMC
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Importance

          Mitochondrial disorders have emerged as a common cause of inherited disease, but their diagnosis remains challenging. Patients with multiple respiratory chain complex defects are particularly difficult to diagnose at the molecular level because of the massive number of nuclear genes potentially involved in intra-mitochondrial protein synthesis, with many not yet linked to human disease.

          Objective

          To determine the molecular basis of multiple respiratory chain complex deficiencies.

          Design

          We studied 53 patients referred to 2 national centers in the United Kingdom and Germany between 2005-2012. All had biochemical evidence of multiple respiratory chain complex defects, and no primary pathogenic mitochondrial DNA mutation. Whole exome sequencing was performed using 62Mb exome enrichment, followed by variant prioritization using bioinformatic prediction tools, variant validation by Sanger sequencing, and segregation of the variant with the disease phenotype in the family.

          Participants

          53 patients with biochemical evidence of multiple respiratory chain complex defects but no primary pathogenic mitochondrial DNA mutation.

          Results

          Presumptive causal variants were identified in 28 patients (53%, 95% CI=39-67), and possible causal variants were identified in 4 (8%, 95% CI=2-18). Together these account for 32 patients (60%, 95% CI=46-74), and involved 18 different genes. These included recurrent mutations in RMND1, AARS2 and MTO1, each on a haplotype background consistent with a shared founder allele, and potential novel mutations in 4 possible mitochondrial disease genes ( VARS2, GARS, FLAD1 and PTCD1). Distinguishing clinical features included deafness and renal involvement associated with RMND1, and cardiomyopathy with AARS2, and MTO1. However, “classical” features were absent in some patients, including normal liver function and Leigh syndrome (subacute necrotizing encephalomyelopathy) seen in association with TRMU mutations, and no cardiomyopathy with founder SCO2 mutations. It was not possible to confidently identify the underlying genetic basis in 21 patients (40%, 95% CI=26-54).

          Conclusions and Relevance

          Exome sequencing enhances the ability to identify potential nuclear gene mutations in patients with biochemically-defined defects affecting multiple mitochondrial respiratory chain complexes. Additional study will be required in independent patient populations to determine the utility of this approach in comparison to traditional diagnostic methods.

          Related collections

          Author and article information

          Journal
          7501160
          JAMA
          JAMA
          JAMA
          0098-7484
          1538-3598
          2 July 2014
          11 June 2019
          : 312
          : 1
          : 68-77
          Affiliations
          [1 ]Wellcome Trust Centre for Mitochondrial Research, Institute for Ageing and Health, The Medical School, Newcastle University, Newcastle upon Tyne, NE2 4HH, UK
          [2 ]Wellcome Trust Centre for Mitochondrial Research, Institute of Genetic Medicine, Newcastle University, Central Parkway, Newcastle upon Tyne, NE1 3BZ, UK
          [3 ]Division of Neuropediatrics and Muscle Disorders, University Medical Center Freiburg, Germany
          [4 ]Department of Neuropediatrics, University of Essen, Essen, Germany
          [5 ]Department of Pediatrics, Hacettepe University, Ankara, Turkey
          [6 ]Department of Paediatrics, University Hospital Center Zagreb & University of Zagreb,School of Medicine, Zagreb, Croatia
          [7 ]Medical Genetics Center, Munich, Germany
          [8 ]Willink Biochemical Genetics Unit, Manchester Centre for Genomic Medicine, Central Manchester University Hospitals NHS Foundation Trust, Manchester, M13 9WL
          [9 ]Department of Paediatric Neurology, Central Manchester University Hospitals NHS Foundation Trust, Manchester, M13 9WL
          [10 ]Department of Paediatric Neurology, Newcastle upon Tyne Hospitals NHS Trust, Newcastle upon Tyne, NE1 4LP
          Author notes
          Corresponding Author: Patrick F. Chinnery PhD FRCP FMedSci, Institute of Genetic Medicine, Newcastle University, Central Parkway, Newcastle upon Tyne, NE2 4HH, United Kingdom ( patrick.chinnery@ 123456ncl.ac.uk )
          Article
          PMC6558267 PMC6558267 6558267 ems83068
          10.1001/jama.2014.7184
          6558267
          25058219
          4d35f183-2c86-4b79-95ca-e887d38577fc
          History
          Categories
          Article

          Comments

          Comment on this article